Clinical trials: Lifestyle-Related Condition
ADHD
Neurobiological Basis of Response to Vyvanse in Adults With ADHD: an fMRI Study of Brain Activation
The purpose of this study is to determine the effects of Vyvanse, an FDA approved medication used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD), on brain activity in adults with attention-deficit…
- Trial name
- NCT01924429
- Testing
- Lisdexamfetamine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jeffrey Newcorn
Attention Deficit Hyperactivity Disorder
A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder
The primary purpose of the study is to assess long-term safety and tolerability of Edivoxetine in pediatric participants with attention deficit hyperactive disorder (ADHD).
- Trial name
- NCT00965419
- Testing
- Edivoxetine
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 267 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Efficacy of GXR as Adjunctive Therapy With Psycho-stimulant on Executive Function in Children With ADHD
This study looks to examine whether or not INTUNIV extended release can help children aged 6-12 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD) in improving Executive Function when added to their usual care…
- Trial name
- NCT01985581
- Testing
- Guanfacine extended release, Stimulant therapy
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- JPM van Stralen Medicine Professional
Impulse Control Disorder, Parkinson Disease
Naltrexone for Impulse Control Disorders in Parkinson's Disease
This study will evaluate the effectiveness of naltrexone in reducing ICD symptoms in Parkinson's disease patients taking a dopamine agonist.
- Trial name
- NCT01052831
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Pennsylvania
Adult Attention Deficit Hyperactivity Disorder
Adult Attention Deficit Hyperactivity Disorder
A Phase 2 study of SEP-225289 in adults with attention deficit hyperactivity disorder (ADHD).
- Trial name
- NCT01692782
- Testing
- SEP-225289
- Where
- 31 sites in United States
- Volunteers
- 341 people
- Sponsor
- Sumitomo Pharma America, Inc.
Post Traumatic Stress Disorder, Attention Deficit Hyperactivity Disorder
Atomoxetine in Veterans With Comorbid ADHD/PTSD
The current available treatments for PTSD are not fully effective for cognitive symptoms of PTSD and have high drop-out and poor engagement, two factors found to be most indicative of overall return to functioning for patients…
- Trial name
- NCT02287038
- Testing
- Atomoxetine 80 MG
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- VA Office of Research and Development
Obesity, Lifestyle-related Condition
Lifestyle Intervention in Preparation for Pregnancy (LIPP)
Studies evaluating lifestyle intervention in obese women during pregnancy have reported limited success in decreasing excessive gestational weight gain, and have failed to achieve the key outcome of breaking the obesity cycle and…
- Conditions
- Obesity, Lifestyle-related Condition, Macrosomia, Fetal
- Trial name
- NCT03146156
- Testing
- Lifestyle Intervention
- Where
- 4 sites in United States
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- Tufts Medical Center
Attention-deficit/Hyperactivity Disorder
Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)
The primary objective of this study is to evaluate the long-term maintenance of efficacy of Extended-Release Guanfacine HCl in children and adolescents (6-17 years) with attention-deficit/hyperactivity disorder (ADHD) who respond…
- Trial name
- NCT01081145
- Testing
- Extended-release Guanfacine Hydrochloride
- Where
- 81 sites in United States, Belgium and 8 more
- Volunteers
- 528 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment
The purpose of this study was to evaluate the effect of SPN-810 for the treatment of impulsive aggression (IA) in adolescents diagnosed with ADHD when taken in conjunction with standard ADHD treatment.
- Trial name
- NCT03597503
- Testing
- SPN-810
- Where
- 38 sites in United States
- Volunteers
- 41 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder
A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine
The purpose of the study is to investigate the relationship of changes in measures of academic performance and problem behaviors, to changes in core Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in Asian children…
- Trial name
- NCT00471354
- Testing
- Atomoxetine
- Where
- 8 sites in China, South Korea and 1 more
- Volunteers
- 228 people
- Sponsor
- Eli Lilly and Company
Mood Disorder, Disruptive Behavior Disorders
Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood Disorders
Irritability and emotional dysregulation are recognized as serious aspects of psychopathology seen in in pediatric psychiatric patients.
- Trial name
- NCT02824627
- Testing
- Oxytocin
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- University of Nebraska
Attention Deficit Hyperactivity Disorder
Atomoxetine Asian Study in Adult Subjects With Attention-Deficit/Hyperactivity Disorder (ADHD)
The primary objective of this clinical study is to assess overall safety and tolerability as measured by discontinuation rate due to adverse events in doses up to 120 mg/day in relation to global clinical studies in adult…
- Trial name
- NCT00636818
- Testing
- Atomoxetine
- Where
- 11 sites in China, South Korea and 1 more
- Volunteers
- 45 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder
An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD).
The study is a phase IIIb multicentre, randomised, placebo controlled, trial in paediatric patients with Attention-Deficit/Hyperactivity (ADHD) and Oppositional Defiant Disorder (ODD).
- Trial name
- NCT00192023
- Testing
- atomoxetine 0.5 mg/kg/day, atomoxetine 1.2 mg/kg/day, atomoxetine 1.2-1.4 mg/kg/day
- Where
- 12 sites in Italy
- Volunteers
- 139 people
- Sponsor
- Eli Lilly and Company
ADHD
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD
This study will evaluate the efficacy and safety of low doses of SPN-812 in adolescents 12-17 years of age.
- Trial name
- NCT03247517
- Testing
- 200mg SPN-812, 400mg SPN-812
- Where
- 12 sites in United States
- Volunteers
- 310 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder, Dyslexia
Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia
This study will evaluate the effects of atomoxetine on brain activation during attention and reading tasks via functional Magnetic Resonance Imaging (fMRI) in participants ages 10 to 16 years old with ADHD and comorbid dyslexia
- Trial name
- NCT00716274
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
New Technologies to Help Manage ADHD
Cluster randomized controlled trial to evaluate the general effectiveness of intervention compared to control on medication continuity as measured by prescriptions written and other more proximal outcomes during the first six…
- Trial name
- NCT02390791
- Testing
- enhanced myADHDportal.com, treatment as usual standard portal
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder
Network Control TMS fMRI
This study uses different types of functional magnetic resonance imagining (fMRI) to generate individual transcranial magnetic stimulation (TMS) targets.
- Conditions
- Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder, Working Memory
- Trial name
- NCT05736458
- Testing
- Transcranial Magnetic Stimulation (TMS), High controllability TMS target
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Attention Deficit Hyperactivity Disorder (ADHD)
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
The study is designed to evaluate the efficacy and safety of SHP465 in the treatment of ADHD in children and adolescents (aged 6-17 years).
- Trial name
- NCT02466425
- Testing
- SHP465
- Where
- 36 sites in United States
- Volunteers
- 264 people
- Sponsor
- Shire
ADHD, Attention Deficit Hyperactivity Disorder
Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301
A Phase 3, randomized, double-blind, placebo-controlled, multi-center, fixed-dose, parallel-group efficacy and safety study in a pediatric population (6-17) with Attention-Deficit/Hyperactivity Disorder (ADHD) using CTx-1301…
- Conditions
- ADHD, Attention Deficit Hyperactivity Disorder, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined
- Trial name
- NCT05286762
- Testing
- CTx-1301-Dexmethylphenidate 12.5 mg (titration only), CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose)
- Where
- 24 sites in United States
- Volunteers
- 103 people
- Sponsor
- Cingulate Therapeutics
Attention Deficit Hyperactivity Disorder
Animal Assisted Intervention With Dogs for Children With ADHD
This pilot study aims to replicate results of a previously studied novel, non-pharmacological psychosocial intervention for children with ADHD, utilizing an Animal Assisted Intervention with therapy dogs combined with traditional…
- Trial name
- PACK-PM (NCT05102344)
- Testing
- Behavioral Social Skills Training, Animal Assisted Intervention
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- University of California, Irvine